Logo
x

Search

Subscribe Now

Outlook Therapeutics

Outlook Therapeutics’ Lytenana Gains the CHMP’s Positive Opinion for the Treatment of Wet AMD

Outlook Therapeutics’ Lytenana Gains the CHMP’s Positive Opinion for the Treatment of Wet AMD

  • March 22, 2024
Outlook Therapeutics Reports EMA's Validation of MAA for ONS-5010 to Treat Wet AMD

Outlook Therapeutics Reports EMA's Validation of MAA for ONS-5010 to Treat Wet AMD

  • December 23, 2022
Outlook Therapeutics Reports the US FDA Acceptance of BLA for ONS-5010 to Treat Wet AMD

Outlook Therapeutics Reports the US FDA Acceptance of BLA for ONS-5010 to Treat Wet AMD

  • October 31, 2022
Outlook Therapeutics Re-Submitted a BLA to the US FDA for ONS-5010 to Treat Wet Age-Related Macular Degeneration

Outlook Therapeutics Re-Submitted a BLA to the US FDA for ONS-5010 to Treat Wet Age-Related Macular Degeneration

  • August 31, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.